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ing a different lipid composition. AdamantylGb3, a soluble Gb3Differential tissue targeting and pathogenesis of verotoxins 1
analogue, competed effectively for Gb3 binding by VT1 andand 2 in the mouse animal model.
VT2 in vitro. However, the effect in the mouse model (onlyBackground. Both verotoxin (VT) 1 and VT2 share the same
measured against VT2, due to the lower LD50, a concentrationreceptor, globotriaosyl ceramide (Gb3). Although VT1 is slightly
required for 50% lethality) was to increase, rather than reduce,more cytotoxic in vitro and binds Gb3 with higher affinity,
VT2 is more toxic in mice and may be associated with greater pathology and further reduce the VT2 serum clearance rate.
pathology in human infections. In this study we have compared Additional renal pathology was seen in VT2  adamantylGb3-
the biodistribution of iodine 125 (125I)-VT1 and 125I-VT2 versus treated mice.
pathology in the mouse. Conclusions. The lung is a preferential (Gb3) “sink” for VT1,
Methods. 125I-VT1 whole-body autoradiography defined the which explains the relatively slower clearance of VT2 and sub-
tissues targeted. VT1 and VT2 tissue distribution, clearance, sequent increased VT2 renal targeting and VT2 mortality in
and tissue binding sites were compared. The effect of a soluble this animal model.
receptor analogue, adamantylGb3, on VT2/Gb3 binding and in
vivo pathology was assessed.
Results. 125I-VT1 autoradiography identified the lungs and
The hemolytic uremic syndrome (HUS) remains thenasal turbinates as major, previously unrecognized, targets,
while kidney cortex and the bone marrow of the spine, long leading cause of acute pediatric renal failure [1]. The syn-
bones, and ribs were also significant targets. VT2 did not target drome comprises acute renal failure, thrombocytopenia,
the lung, but accumulated in the kidney to a greater extent and microangiopathic hemolytic anemia [2]. Most oftenthan VT1. The serum half-life of VT1 was 2.7 minutes with
HUS is a complication of gastrointestinal infection with90% clearance at 5 minutes, while that of VT2 was 3.9 minutes
verotoxin (VT) producing enterohemorrhagic Esche-with only 40% clearance at 5 minutes. The extensive binding
of VT1, but not VT2, within the lung correlated with induced richia coli (EHEC) [3, 4]. Several serotypes of EHEC
lung disease. Extensive hemorrhage into alveoli, edema, alveo- bacteria have been implicated in disease, but E. coli
litis and neutrophil margination was seen only after VT1 treat-
O157:H7 is the predominant EHEC serotype associatedment. VT1 targeted lung capillary endothelial cells. Identical
with HUS in North America and Europe [5, 6]. EHECtissue binding sites (subsets of proximal/distal tubules and col-
lecting ducts) for VT1 and VT2 were detected by toxin overlay bacteria elaborate either or both of two serologically
of serial frozen kidney sections. Glucosuria was found to be a distinct VTs: VT1 and VT2. VTs show a high degree of
new marker of VT1- and VT2-induced renal pathology and homology with Shiga toxin, produced by Shigella dysen-positive predictor of outcome in the mouse, consistent with
teriae 1, and hence are also referred to as Shiga toxin 1VT-staining of proximal tubules. Lung Gb3 migrated on thin-
and Shiga toxin 2, respectively.layer chromatography (TLC) faster than kidney Gb3, suggest-
After synthesis in the intestine, the toxins may reach
the systemic circulation by transcellular translocation1 Current address: Faculty of Medicine, University of Groningen, Gron-
ingen, The Netherlands through intestinal epithelial cells [7, 8] aided by neutro-
phil migration in the opposite direction [9]. Recent inves-
Key words: biodistribution, lung and renal pathology, globotriaosyl
tigations in vitro [10] and in vivo [11] have shown thatceramide, glycolipid analogue, adamantylGb3, glucosuria, Shiga-like
toxin. VTs bind to monocytes without inducing cytotoxicity.
This is postulated to be a possible mechanism of trans-
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antigen) [12]. Various cells in the human body express stability. These authors also noted that VT1-treated mice
died in the absence of excessive renal pathology, sug-this receptor, but most common complications of EHEC
gesting that the fatal effects lay in a different organinfection are hemorrhagic colitis, HUS, and neurological
system. These studies also showed that the Gb3 bindingdysfunction [13].
affinity for VT2 was, like VT2c [47], approximately 10-VTs are A:B5 subunit toxins, consisting of five recep-
fold lower than that of VT1 [46].tor-binding subunits (B subunit) and one enzymatically
In rabbits, VT1 is more lethal than VT2. Brain lesionsactive subunit (A subunit). Upon binding to Gb3 via the
can be induced by VT2, but not VT1, whereas VT1-B-pentamer, the toxin is internalized via clathrin-coated
induced spinal cord lesions can be seen [48, 49]. VT2,pits and caveoli-mediated endocytosis [14–16]. Once in-
although generally less cytotoxic than VT1 in vitroternalized, the toxin undergoes a process of retrograde
[50, 51] shows increased cytotoxicity for cultured humantransport to the Golgi and/or endoplasmic reticulum
renal microvascular endothelial cells [52]. The A subunit[17, 18]. The mechanistic paradigm is that the A subunit
of VT2, but not VT1, was recently found to contain ais cleaved into an A1 and an A2 fragment and the A1
sequence capable of binding anti-apoptotic partners thatfragment then targets the 28S RNA portion of 60S ribo-
prevent Bcl-2 action, which may provide a second mecha-somal subunits in the cytosol and by so doing disrupts
nism for VT2-induced cell killing [53].ribosomal function of protein production resulting in cell
In this study we expanded on the mouse model of VTdeath. While inhibition of cellular protein synthesis is
by defining the biodistribution and clearance characteris-clearly established, VT appears to have diverse intercel-
tics of VT1 and VT2. This data show significant differ-lular actions. VT induces apoptosis, a process requiring
ences in tissue targeting and clearance of VT1 and VT2,protein synthesis, in many cell types [19–25] and can
which could explain the distinct toxicities observed ininduce specific gene expression [26–31]. VT can depuri-
mice and, perhaps, relate also to the differential pathol-nate DNA as well as RNA [32, 33]. Intracellular tar-
ogy in humans.geting of the holotoxin to the endoplasmic reticulum and
VT1 and VT2 binding to the receptor Gb3 plays thenucleus has been associated with high VT sensitivity
primary role in determining tissue targeting and suscepti-[18, 34]. Thus, the exact mechanism or combination of
bility in rabbits [54, 55]. Prophylactic attempts to com-mechanisms by which VTs kill cells remains speculative
pete with insoluble Gb3 analogues within the gastrointes-[35, 36].
tinal tract have proven ambiguous [56], possibly becauseIn human kidneys, Gb3 is expressed by endothelial cells VT may be transcytosed directly across the intestinal(and epithelial cells [37]) located primarily in the pediat-
epithelium from the site of bacterial attachment and isric glomerulus and, to a lesser extent, in the tubules [38].
receptor independent [9]. A different approach would
Glomerular Gb3 expression is reduced or lost in the adult be to use soluble Gb3 analogues to prevent systemic VTkidney [38], despite the fact that the total level of renal tissue targeting. Analysis of the serum Gb3 levels in VTGb3 is increased [39]. The ontologically regulated glo- producing E. coli-infected patients who did or did not
merular expression of Gb3 may explain the fact that HUS develop HUS showed that the level was higher in the
mainly occurs in young children [38]. This has been re- non-HUS patients [57], suggesting that soluble Gb3 ana-cently supported by the detection of VT2 in glomeruli of logues could indeed, prove an effective prophylactic.
pediatric, but not geriatric, VT producing E. coli-induced High-affinity VT/Gb3 binding requires the lipid moiety
HUS cases [40]. At autopsy, glomerular lesions are seen. [58] and, if administered to compete in such a format,
Changes noted include glomerular endothelial cell swell- would likely partition into cells to provide additional VT
ing, thromboses, congested glomeruli, arteriolar throm- receptors, rather than fewer. The weakly VT-binding
boses, which are common at the hilum of glomeruli and galactose (1-4) galactose disaccharide from Gb3 can
are sometimes seen proximally, including in interlobular be appropriately multimerized to provide a structure
arteries, and in the most severe cases, cortical infarction. capable of cross-linking (and hence inactivating) VT B
These changes are assumed to be responsible for the subunits to effectively prevent VT cytotoxicity [59, 60]
acute renal failure observed [41]. in vitro. Our approach has been to develop monomeric
Epidemiological studies have suggested that patients soluble Gb3 analogues that retain high-affinity VT bind-
infected with EHEC producing VT1 in combination with ing [61]. We have now tested the ability of such a species
VT2 or VT2 alone were more prone to develop serious to alter the biodistribution and toxicity of VT2 in the
complications like HUS than patients infected with mouse model.
EHEC producing VT1 alone [42–45]. Tesh et al showed
a clear difference between in vivo toxicities of VT1 and
METHODSVT2 in mice [46]. Their studies showed a 400-fold lower
ReagentsLD50 for VT2 and that VT2 caused greater renal pathol-
ogy than VT1. It was thought that the difference in toxic- Monoclonal antibody (mAb) PH1, specific for the VT1
B subunit, has been previously described [62]. PH1 wasity could partially be explained by a difference in toxin
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purified from culture supernatant using Protein A-sepha- tabolism and Pharmacokinetics Division, Lawrence, KS,
USA). Mice were pretreated with oral potassium iodiderose chromatography. Rabbit polyclonal antiserum against
the purified VT1 B subunit was prepared, as previously 24 hours prior to injection of 125I-VT1 to block thyroid
uptake of any free 125I. 125I-VT1 (1.12 g) was adminis-described [63]. Rabbit antiserum raised against VT2e
and reactive with VT2 was a generous gift of Dr. Carlton tered intravenously through the tail vein and the animals
were sacrificed by CO2 inhalation 15 minutes (N  2)Gyles, University of Guelph, Guelph, Canada. Antibody
against the facilitative glucose transporter GLUT-2, se- or 45 minutes (N  3) later. Animals were frozen in
hexane/dry ice and embedded in carboxymethyl cellu-lectively expressed in the S1 segment of proximal tubules
[64, 65], was obtained from Alpha Diagnostic Interna- lose. Sagittal cryosections (40 M) using a Richert-Jung
Polycut S cryomictrotome (Leica Microsystems, Inc.,tional, Inc. (San Antonio, TX, USA). Biotinylated Dol-
ichos biflorus agglutinin (which binds -N-acetyl galac- Bannockburn, IL, USA) were collected on adhesive tape,
dried, and exposed to Kodak SB-5 x-ray film. Hematoxy-tosamine, highly expressed in collecting ducts [66]) and
peanut agglutinin (which binds terminal -galactose and lin and eosin (H&E) stained sections used for autoradi-
ography were used for tissue assignment.galactosyl (-1,3) N-acetylgalactosamine; distal tubules)
were purchased from Vector Laboratories (Burlingame, Quantitative tissue distribution. Mice were injected via
the tail vein with 2 g/kg 125I-VT1 or 125I-VT2 (about 50CA, USA).
ng/mouse) diluted in 200 L saline. In these studies, no
Toxins allowance for the difference in LD50 values for these
toxins was made and pathologic-induced changes forVT1 was purified from strain JB28 [67], as previously
described [68]. VT2 was purified from E. coli R82pJES1- VT2 might have occurred. Pilot experiments were per-
formed to examine toxin distribution at 1, 2, or 8 hours20DH5a, kindly provided by Dr. J. Samuel (Texas A&M
University, College Station, TX, USA). Nucro-Technics, post injection and the effects of perfusion prior to tissue
collection on the biodistribution data obtained. For finalInc. (Toronto, Ontario, Canada) analyzed purified toxins
for endotoxin using the Limulus amoebocyte lysate clearance/biodistribution studies, groups of mice (N  8)
were injected with toxin and a 50 L blood sample wasmethod. VT1 had 0.1 EU/g (10 pg/g) while VT2
had 12.5 EU/g (1.25 ng/g). These lipopolysaccha- obtained from the lateral saphenous vein at 5 and 30
minutes post injection. At 60 minutes post injection, miceride (LPS) levels are far below those shown to cause
synergistic or protective effects on VT2 pathology [69]. were anesthetized (0.1 mL/g 3.6% chloral hydrate intra-
peritoneally) and a 200 L blood sample was obtainedPurified toxins were labeled with iodine 125 (125I) using
iodogen, as described previously [70]. The protein con- from the orbital plexus. Upon taking the last blood sam-
ple, mice were sacrificed immediately by cervical disloca-centration of the isolated iodinated VTs was determined
using the bicinchoninic acid (BCA) protein assay (Pierce tion and tissues were removed for analyses of radioactiv-
ity using a gamma counter.Chemical Co., Rockford, IL, USA). Greater than 97%
of recovered radioactive material was protein-bound as
Effect of adamantylGb3 on VT2 biodistributiondetermined by trichloroacetic acid precipitation. Specific
activities were typically 8 to 12  106 cpm/g for VT1 The semi-synthetic, soluble Gb3 derivative, N-ada-
mantylGb3 (adaGb3), was prepared from human renaland VT2. To verify that radiolabeling of the toxins did
not affect activity, a Vero cell cytotoxicity assay was Gb3, as previously described [61]. Two groups of mice
(N  8) were injected intravenously with a mixture ofperformed to compare labeled and unlabeled toxin. Io-
dinated VT1 was heat-inactivated by treatment at 90 to 4 mg/kg adaGb3 and 2g/kg 125I-VT2 (representing about
100 g (100 nmol) of adaGb3 and 50 ng VT2 (0.7 pmol)100C for 30 minutes. Binding of denatured toxin to
Vero cells was reduced by 	90% compared to native per mouse) in 200 L. The procedures followed matched
those used in the biodistribution studies discussed above.125I-VT1.
Mice Clinicopathologic studies with VT2 challenged mice
The LD50 of VT2 in mice is 400-fold lower than thatThe mice were 12- to 16-week-old female BALB/c
mice (weight range, 20 to 30 grams) that were purchased of VT1 [46]. Therefore, VT2 was chosen for in vivo
protection studies using adaGb3. Initial studies showedfrom Charles River, Canada. Male mice were used in
the whole-body autoradiography studies. The mice were that a dose of 2 ng/mouse (80 ng/kg) caused development
of fatal disease in 100% of mice 80 to 105 hours post-maintained under a 12-hour light-dark cycle and fed with
standard diet and water ad libitum. injection. This dose represents 1.5 to 4 times the reported
LD50 in Balb/c mice [69, 71].
Biodistribution The ability of adaGb3 to alter the VT2 disease course
with respect to clinical, biochemical, and histologic symp-Whole-body autoradiography. Whole-body autoradi-
ography was performed by Oread Biosafety, Inc. (Me- toms was investigated. In all cases, mice were injected
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intravenously through the tail vein (N  5) for each tavidin peroxidase system. Sections were counterstained
with hematoxylin, dehydrated, and mounted. Serial sec-group. Group 1 received 2 ng (80 ng/kg) VT2. Group 2
received a mixture of 2 ng VT2 and 100 g (4 mg/kg) tions were also stained with PAS, anti-GLUT-2, biotinyl-
ated Dolichos biflorus agglutinin, peanut agglutinin, oradaGb3. Group 3 was injected intravenously with 4 mg/kg
adaGb3 alone. A fourth group of mice (N  3) was 1% goat serum/PBS as antibody control.
injected intravenously with sterile saline alone. AdaGb3-
In situ immunodetection of targeted VTVT2 mixtures were pre-incubated for 20 to 30 minutes
at room temperature prior to injection. Mice were injected through the tail vein with 10, 50 or
100 g of VT1 or VT2 in 200 L of saline. After 1 hour,In experiments involving blood collection, 24 hours
prior to injection, a 200 L blood sample was taken from the animals were sacrificed by cervical dislocation and
organs were collected and divided. Half was placed inthe lateral saphenous vein. At 72 hours post injection,
mice were anesthetized with chloral hydrate (3.6% 0.01 O.C.T compound and snap-frozen in liquid nitrogen for
preparation of frozen sections. The remainder was placedmL/g intraperitoneally) and a 300 L blood sample was
taken from the orbital plexus. After obtaining the second in neutral buffered formalin for a minimum of 16 hours
before being paraffin-embedded and sectioned.blood sample, mice were immediately sacrificed by cervi-
cal dislocation and tissues were processed as described VT was detected in the frozen sections essentially as
described above for VT staining of frozen kidney sec-under Histopathology below.
All blood samples were collected with heparinized tions, with the following two exceptions. The frozen sec-
tions were fixed with 100% acetone for 10 minutes priorcapillary tubes. Blood was centrifuged immediately upon
collection, plasma and cells were separated, and plasma to assay rather then dried overnight, and the VT1 binding
step was omitted. Tissues from mice injected with salinewas stored at –20C until analysis. To monitor for signs
of renal dysfunction, plasma samples were analyzed for rather than VT served as controls for non-specific bind-
ing of anti-toxin antibodies.blood urea nitrogen (BUN) and creatinine at the Depart-
ment of Pediatric Laboratory Medicine, Hospital for Sick Paraffin sections were de-paraffinized by immersion in
xylene, followed by baths of decreasing ethanol contentChildren, in Toronto, Ontario, Canada. Blood glucose
levels were measured using a One Touch Basic blood (100%, 95%, 70% ethanol in water), and finally, water.
After de-waxing, antigen retrieval was required for de-glucose monitoring system (Lifescan Canada, Ltd., Bur-
naby, B.C., Canada). Urine samples were collected upon tection of VT in kidney sections. Antigen unmasking
was performed by heating the de-waxed sections in 0.01spontaneous voiding. Using Albustix (Bayer, Inc., To-
ronto, Ontario, Canada), urine was analyzed for glucose, mol/L citrate buffer pH 6, in a pressure cooker [73].
protein, pH, specific gravity, erythrocytes, and leukocytes.
VT TLC overlay
Histopathology Glycosphingolipids (GSLs) were extracted from lungs
and kidneys (pooled from 5 animals) as previously de-Animals treated with VT1, VT2, VT2  adaGb3,
adaGb3, or saline were sacrificed by cervical dislocation. scribed [39] and equivalent aliquots according to tissue
weight were separated by TLC and overlaid with eitherKidney, lung, brain, spleen, and liver were fixed in neu-
tral-buffered formalin and then paraffin-embedded and VT1 or VT2 [74]. Toxin binding was visualized using ECL
detection (Amersham Biosciences, Piscataway, NJ,sectioned. All sections were stained with H&E and, in
addition, kidney sections were stained with periodic acid- USA).
Schiff (PAS) to identify the brush-border of proximal
Statistical analysistubules.
Results are expressed as the mean
 standard deviation.
VT staining of frozen kidney sections
A fresh tissue sample was placed in Tissue-Tek O.C.T.
RESULTS
compound (Miles, Inc., Diagnostics Division, Elkhart,
Whole-body autoradiography afterIN, USA) and snap-frozen in liquid nitrogen. Serial 6 m
125I-VT1 administration.frozen sections were cut and stored at –70C. The immu-
noperoxidase VT staining was performed, as described Several illustrative sagittal sections are shown in Fig-
ure 1. No additional organs were labeled in other sections.[72]. Sections were dried overnight and then blocked
separately for endogenous peroxidase, avidin, and biotin. VT1 labeling of the kidney cortex, lung, and the nasal
turbinates were the most prominent features of the auto-The sections were incubated with 50 ng/mL of VT1 or
VT2 diluted in 1% goat serum/phosphate-buffered saline radiogram (Fig. 1). Labeling of the bone marrow of the
spine, long bones, and ribs was also extensive. The labeling(PBS) for 30 minutes. After washing, polyclonal anti-
VT1 or anti-VT2 was added and bound antibody was in the lung could be seen to be non-uniform since bronchi-
oles were not labeled and foci within the lung could bedetected with a biotinylated goat anti-rabbit IgG-step-
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Fig. 2. Serum clearance of 125I-VT1 and 125I-VT2. Approximately 50 ng
125I-labeled toxin was injected into mice intravenously (N  8) and
counts remaining in circulation over the next hour were measured. The
effect of mixing the semi-synthetic soluble Gb3 derivative N-ada-
mantylGB3 (adaGb3) with 125I-VT2 prior to injection was also deter-
mined. (), 125I-VT1; (), 125I-VT2; (), 125I-VT2  adaGb3.
counts injected. To compare clearances of both VT1 and
VT2, the amount of toxin as measured in the blood
samples was expressed as a percentage of injected counts
recovered in 50 L blood (Fig. 2). Within 5 minutes,
90% of injected VT1 but only 40% of injected VT2 was
cleared. After 60 minutes there were sixfold less counts
circulating for VT1 than for VT2. The estimated half-
lives for VT1 and VT2 were 2.7 and 3.9 minutes, respec-
tively, based on the decrease in counts between time
points 0 and 5 minutes.
Biodistribution. All measurements were at 1 hour post
injection. Both groups of mice injected with 125I-VT1 or
VT2 showed tissue localization of the toxins primarily
in the lungs and nasal turbinates (Fig. 3) consistent with
the autoradiography study (Fig. 1). Toxin targeting to these
Fig. 1. Autoradiography of 125I-VT1 injected mouse. Sample sagittal organs has not been previously reported. However, VT1
sections from several mice are shown with labeled tissues indicated. showed a 10-fold higher lung targeting than VT2. VT2The lower panel highlights the non-uniform labeling in the lung seen
preferentially targeted kidneys (2.7-fold that of VT1),on reduced exposure.
whereas VT1 spleen targeting was twofold that of VT2.
Heat inactivation, for the most part, eliminated tissue
targetting (Fig. 3). Increased levels of the inativated VT1
distinguished on less exposure (Fig. 1, lower panel). The in the liver and kidney probably reflect clearance of the
spleen was significantly labeled, but less than lung. The denatured protein.
liver was barely labeled above the background. No label- The biodistribution of 125I-VT1 was also compared in
ing of the gastrointestinal tract, central nervous system, male and female outbred CD1 mice. Pulmonary and renal
brain stem, spinal chord, testes, lymph nodes, thymus, re- VT1 accumulation was40% higher in male than female
productive tract, pancreas, blood, skeletal/cardiac muscle, animals, consistent with the greater (renal) Gb3 content
dermis, or epidermis was seen. in males [76], but otherwise, distribution was not signifi-
cantly different from BALB/c mice (data not shown).
Tissue distribution of 125I-VT1 and 125I-VT2
VT1 and VT2 immunolocalizationClearance. Blood samples were taken at three different
time points. Because blood was not collected before 5 min- Kidney. VT1 and VT2 were immunolocalized in fixed/
utes, the data for zero time points were calculated from paraffin-embedded or frozen renal sections from mice 1
hour after 10, 50 or 100 g of VT1 or VT2 had beenthe estimated blood volume for each mouse [75] and the
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Fig. 3. Biodistribution of 125I-VT1 and 125I-VT2. Approximately 50 ng 125I-labeled toxin was injected into mice intravenously (N  8). After 1 hour,
the toxin distribution to various tissues was determined and expressed as the percentage of injected counts per minute recovered per mg of tissue.
(), heat-denatured VT1; (), VT2; ( ), VT1.
injected (Fig. 4). The VT1 and VT2 immunostaining structures labeled by both VT1 and VT2 as collecting
ducts (Fig. 5e), while immunostaining with anti-GLUT-2patterns were similar. Immunostaining was clear in the
[64] identified others as proximal convoluted tubulesfrozen sections, even at the 10 g dose, but morphology
(Fig. 5f). Some distal tubules labeled with peanut aggluti-was better preserved in the fixed, embedded sample.
nin [77] were labeled with VT1 or VT2, but most wereClear staining of distinct tubule subpopulations was seen
not (Fig. 5g).for both toxins. No glomerular staining was seen (Fig.
Lung. Frozen-section immunostaining of VT1 accu-4 A to C). In the paraffin sections, it was clear that VT-
mulated in the lung following intravenous injection showstargeted tubules were dilated and the epithelial cells
areas of some intra-alveolar capillaries, and patches offlattened, even after this short period (Fig. 4 C, D). This
pneumocytes within the alveoli are targeted (Fig. 6).effect was dose dependent. Immunodetection of targeted
Distinct, sometimes discontinuous, subpopulations ofVT1 in the unmasked paraffin sections was adequate at
endothelial cells within some capillaries were labeled.100 g but poor at 50 g (and not detectable at 10 g).
Epithelial cells were, for the most part, VT1-negative.Nevertheless, the dismorphic tubules could be identified
VT could not be detected in the paraffin sections perhaps
in the H&E section and the corresponding stained tubule due to a failure to unmask the antigen in this tissue
identified (for the 50 and 100g dosage). Dilated tubules with the conditions used. Gb3 was detected in untreated
were less apparent in H&E stained sections at the 10 g mouse lung frozen sections by VT1 overlay, but the mor-
dosage (not shown). phology was not sufficiently retained to allow identifica-
By overlay of (untreated) mouse kidney frozen sec- tion of cell targets.
tions, both VT1 and VT2 were found to bind exactly the
Pathologysame tubular structures (Fig. 5). Neither toxin bound
to glomeruli (Fig. 5 a, b). Labeling serial sections with Kidney. Mice injected with 1.5 to 4 LD50 (VT1 or
VT2) showed kidney pathology, characteristic of tubularthe lectin D. biflorus [66] identified some of the renal
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Fig. 4. Immunolocalization of kidney-tar-
geted VT1 and VT2. Frozen (A, B) or fixed,
paraffin-embedded (C, D) sections of kidney
were prepared from mice 1 hour after injec-
tion with either 50 g VT1 or VT2 and stained
with antiserum against VT1 (A, C) or VT2
(B). A similar subpopulation of tubules are
labeled by each toxin but neither bound to
glomeruli (arrows). In fixed sections, tubules
targeted by VT1 (C) were identified in hema-
toxylin and eosin (H&E)-stained serial sec-
tions as dilated and containing flattened epi-
thelial cells (D).
necrosis as previously reported [46] by day 3. Glomerular some edematous material was lost during tissue prepara-
tion/staining (Fig. 7L). Edema of larger blood vesselsmorphology appeared normal. A significant subpopula-
was evident (Fig. 7K). Margination of neutrophils intion of proximal and especially distal tubules were dilated
venules was extensive (Fig. 7H) and infiltration of typein both VT1- and VT2-treated mice. Medullary tubular
II pneumocytes was evident. In contrast, in VT2-treateddilation was more widespread after VT1 treatment. In-
animals, there was some slight edema and neutrophilterstitial hemorrhage was seen for all VT-treated mice.
margination evident, but lung histology was, for the mostNeutrophil migration to sites of tubular injury was not
part, indistinguishable from controls (Fig. 7 B, E, H com-seen. Apoptosis, as monitored by terminal deoxy trans-
pared with C, F, I).ferase uridine triphosphate nick end-labeling (TUNEL)
Other. Active acute phagocytosis was present in focistaining, was not increased in the kidneys of VT-treated
in the spleen after either VT2 or VT1 treatment. TUNELmice (not shown). Glucose was detected in the urine of
staining revealed increased apoptosis in spleens of VT1VT-treated mice after 3 to 4 days, before the onset of
or VT2 but not in saline-treated mice (not shown). Also,any visible symptoms (Table 1) and was present until
iron pigment from increased red cell turnover was evi-the time of death. Glucosuria was an excellent predictor
dent in the spleen of toxin-treated mice.of mortality (Table 1). Co-administration of the neu-
In the liver, lipid vacuoles were seen in VT2-treatedtralizing anti-VT1 mAb PH1 [62] with VT1 completely
animals but were less apparent for VT1-treated animals
protected mice from pathology and development of glu-
(not shown).
cosuria (Table 2). VT-treated mice did not become an-
uric, but did develop a urine-concentrating defect (Ta- Tissue Gb3 content
ble 1). Using urinalysis sticks, no changes in urinary The Gb3 content of glycolipid extracts of lung and
protein concentration, pH, or specific gravity was mea- kidney was visualized by VT1 and VT2 TLC overlay
sured. but erythrocytes and leukocytes were sometimes (Fig. 8). The mouse renal Gb3 migrated more slowly than
detected in urine of moribund mice. that from lung. VT2/Gb3 binding was significantly less
Lung. Lung sections of 2 LD50 [78] VT1-treated mice than that of VT1. A dose-dependent binding to human
showed significant hemorrhage (Fig. 7 A, E, J) and marked renal Gb3 standard was seen, and both toxins efficiently
alveolitis was apparent (Fig. 7 E, H). The lungs had a recognized adaGb3.
congested appearance (Fig. 7H) with thickened edema-
Treatment with a soluble Gb3 analogtous alveolar walls showing numerous entrapped erythro-
cytes (Fig. 7L). Edema within alveoli was also seen (Fig. The water-soluble Gb3 derivative, adaGb3 [61], was
effective to prevent VT1 and VT2 binding to immobi-7L). The edema was often discontinuous, suggesting that
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Table 1. Biochemical parametersa of VT2-treated mice
Blood glucose Plasma urea Plasma creatinine Clinicalb disease Colorc
Treatment Glucosuria mmol/L mmol/L lmol/L at 72 hours of urine
Baseline  4.72
0.6 6.43
1.27 21.2
2.4  
(N  32) (N  43) (N  39)
2 ng VT2  (0/5) 4.84
0.84 9.92
2.0 27.0
3.24  
2 ng VT2  adaGb3  (5/5) 4.50
0.43 24.6
4.0 55.0
5.66  (5/5) 
adaGb3  (0/5) 4.76
0.65 6.28
0.63 22.4
2.6  
4 ng VT2  (0/5)d 5.68
0.26 16.2
7.9 45.3
26.1  (1/5)
4 ng VT2  adaGb3  (4/5)e 4.22
0.85 24.6
5.8 69.3
5.8  (4/6)
adaGb3  (0/5) 5.04
0.84 6.8
1.0 22.2
4.6  (0/5)
a Parameters monitored at 72 hours post injection
b Ruffled fur, inactive
c VT-treated mice developed urine-concentrating defect and when moribund had nearly colorless urine () in contrast to untreated mice ()
d Glucosuria was detected at 96 hours
e No urine obtained from one of five mice
Table 2. Clinical parameters of mice treated with VT1
PH1
monoclonal antibodies (mAb)
Time of Urine glucose Clinical Color
Treatment deatha hour mmol/L disease of urine
1.2 g VT1 58.5 nd  nd
1.2 g VT1 58.5 14–28  
1.2 g VT1 68 	14  
1.2 g VT1  PH1 68   
1.2 g VT1  PH1 68   
1.2 g VT1  PH1 68   
a VT1-treated mice were sacrificed when moribund and healthy PH1-protected
animals were sacrificed for analysis of histopathology
lized Gb3 as monitored by receptor enzyme-linked immu-
nosorbent assay (RELISA) (Fig. 9). The IC50 for VT1
was10mol/L [61] while that for VT2 was higher (50
mol/L). Due to the much lower LD50 in mice, we used
VT2 to determine whether this protection in vitro could
be effective in vivo. We mixed 500 mol/L adaGb3 with
approximately 1 LD50 VT2 and injected it into the ani-
mals. Surprisingly, mice co-injected with VT2  adaGb3
were found to die more rapidly than those injected with
VT2 alone (96 hours compared with 72 hours). Indeed,
since a near-LD50 dose was administered, in some cases,
Fig. 7. Comparison of VT1 and VT2 induced lung pathology. Micethe mice treated with VT2 alone survived (Table 1).
(N  3) were injected with 2 LD50 of VT1 [102] or VT2, or with saline.Glucose was detected in the urine of VT2  adaGb3- Toxin injected mice were sacrificed when moribund and saline-treated
treated mice earlier than for mice given VT2 alone (Ta- mice at corresponding time points. Hematoxylin and eosin (H&E) stain-
ing of lung of VT1 (A), VT2 (B), and saline (C ) treated mice; adjacentble 1). AdaGb3 alone at this dosage had no obvious toxic
blood vessel and alveoli in VT1 (D), VT2 (E ) and saline (F ) treatedeffect in mice and renal histology was normal (Fig. 10 A,
mice; alveoli of VT1 (G), VT2 (H ) and saline (I ) treated animals. In
D, G). In the VT2 adaGb3-treated mice, many tubular VT1-treated mice, alveolar hemorrhage (J ), blood vessel edema (K ),
and alveolar edema (L) were widespread.epithelial cells were swollen. This was seen in the cortex,
but particularly in the medulla, such that many tubule
lumina were occluded (Fig. 10 C, F). Evidence of epithe-
lial cell detachment from the basement membrane is
brain pathology was seen for VT1-, VT2- , or VT2 seen in both VT2- and VT2 adaGb3-treated mice. The
adaGb3-treated mice.epithelial morphology of the affected tubules was more
Comparison of the biodistribution of 125I-VT2 with anddysplastic, and more granular eosinophilic spheres in the
without adaGb3 showed that, in most tissues, VT2 tissuetubular lumina (Fig. 10 H, I), typical of acute tubular
necrosis, were seen for VT2  adaGb3-treated mice. No targeting was marginally increased, rather than de-
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Fig. 10. Effect of AdamantylGb3 (adaGb3)
on VT2-induced renal pathology. Mice (N 
5) were injected intravenously with adaGb3,
VT2, or a mixture of VT2 and adaGb3. Ani-
mals were sacrificed at 72 hours post injection
and hematoxylin and eosin (H&E) stained
paraffin sections of renal tissue were inspected
for pathology. (A, D, G), adaGb3-treated
mice; (B, E, H), VT2-treated mice; (C, F, I ),
VT2 adaGb3-treated mice. (A to C), cortex;
(D to F), medulla; (G to I), tubules at high
power. Glomerular morphology appears unaf-
fected by VT2 (B). The tubular dilation (B
and E) are reversed in the VT2  adaGb3
mice (C, D). The epithelial cell narrowing (E
and H) after VT2 treatment is also reversed,
but the epithelial cells of many tubules now
become enlarged such that their lumina are
occluded (F). The epithelial cell layer of tu-
bules of VT2-treated mice was often dismor-
phic (H) and the frequency of eosinophilic
nuclei (in dying cells) increased after VT2 
adaGb3 treatment (I, arrows)
creased, in the presence of adaGb3 (results not shown).
This was consistent with the finding that the serum half-
life for 125I-VT2 was increased to 8.7 minutes in the pres-
ence of adaGb3 (Fig. 1).
DISCUSSION
VT-induced cell cytotoxicity [79, 80] and likely in vivo
pathology [38] are mediated by binding to its glycolipid
receptor, globotriaosyl ceramide [12]. Can this binding
in any way explain the increased sensitivity of mice (and
humans?) to VT2? The binding of VTs to Gb3 is differen-
section corresponding to A and B stained with non-immune serum.Fig. 6. Immunolocalization of lung-targeted VT1. Frozen sections of
lung were prepared from mice 1 hour after injection with 50 g VT1. Discontinuous staining of endothelial cells lining a capillary is indicated
in (B). Continuous staining of endothelial cells within a capillary is(A), Hematoxylin and eosin (H&E) stain; (B), corresponding serial
section stained with anti-VT1; (C ), anti-VT1 immunostaining; (D), lung shown in (C). Some staining of pneumocytes is also evident.
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Fig. 5. Comparison of VT1 and VT2 binding sites in frozen kidney sections. Serial frozen sections of kidney were stained with VT1 (a, c) or VT2
(b, d), the lectin Dolichos biflorus (e), anti-GLUT2 ( f), peanut agglutinin (g) and periodic acid-Schiff (PAS; h). Both toxins label the same collecting
ducts and proximal tubules. Comparison staining of the equivalent areas is shown (c to h). A representative glomerulus unstained by VT1 or VT2 is
shown (a and b). Four collecting ducts labeled with D. biflorus and VT1, VT2 are indicated (e). The arrowhead indicates a D. biflorus-reactive
collecting duct, not labeled with peanut agglutinin (g). Proximal tubules reactive with VT1, VT2 and anti-GLUT2 are indicated (f). Anti-VT2 renal
staining after in vivo VT2 administration ( j) is compared to PNA staining (i) of serial sections. A VT2-negative, PNA-positive distal tubule is marked
* (i), while a PNA-negative, VT2-positive proximal tubule is marked * ( j). Distal tubules labeled by both PNA and VT2 are indicated by arrows.
tially modulated by the lipid content of the glycosphingo- place. Glucose appeared in the urine approximately 3
to 4 days after VT injection and prior to the onset oflipid (GSL) [58, 81, 82] and also by the phospholipid
content of the membrane in which it is contained [83]. any visible symptoms. Acute pancreatitis as a cause of
glucosuria was excluded by showing that there was noDue to the extensive repertoire of such modulation,
Gb3-mediated tissue targeting of these VTs subtypes increase of the blood glucose over time. Using Albustix
to detect urinary glucose proved an easy and inexpensivecould be distinct and is likely complex. Although our
way to monitor disease development in mice. Urinaryoriginal studies compared the Gb3 binding of VT1 to that
glucose was seen for VT1- or VT2-treated animals andof VT2c [82], rather than VT2, VT1 and VT2 receptor
an absolute correlation with eventual death was seen.binding is distinguishable [84]. Although the different
Co-administration of mAb anti-VT1 protected micemembers of the VT family all bind Gb3, this recognition is
against VT1-induced mortality and development of glu-slightly different in each case, since removal of individual
cosuria. VT2 mortality was exacerbated by adaGb3, andhydroxyl groups within the terminal galabiose moiety
urinary glucose was detected earlier in such mice. How-has a differential effect on the binding of each toxin
ever, increasing VT above a lethal dosage did not in-variant [74].
crease the level of glucosuria.Whole-body autoradiography has identified new tissue
The murine renal VT distribution does not correlatetargets for VT1, specifically the nasal turbinates and the
with the pathology observed in human pediatric HUSlung. No binding to neural, reproductive, or gastrointesti-
where mainly glomeruli are affected by the toxins [4, 41,nal tissue was seen. Binding within the spleen and bone
88] or with VT binding in pediatric renal sections [38, 89].marrow confirms the VT propensity for lymphoid cells
Glucosuria has not been reported in humans and this[85–87].
may prove another distinction between this model andOur results show a decreased clearance rate and an
HUS. However, HUS patients have been shown to haveincreased binding in kidneys for VT2 when compared
urinary markers of proximal tubule pathology early into VT1, which was primarily recovered in the lungs.
the course of disease [90] and evidence of tubular cell
Renal targeting death [91, 92]. Several studies have reported that cul-
tured proximal tubule cells are highly sensitive to VT1VT1 and VT2 have the same pattern of binding in
the kidney, determined either by immunolocalization of [23, 93, 94]. The distribution of VT in the murine kidney
is similar to that seen in overlays of sections of adultkidney-targeted VT or by frozen-section VT overlay,
both targeting proximal and distal tubules and collecting human kidneys [38], which, on an epidemiological basis,
are less susceptible to VT-induced HUS.ducts. By both approaches, no labeling of glomeruli was
seen. Detection of in vivo renal-targeted VT1 shows that In situ detection of in vivo kidney-targeted VT better
mimics the normal pathophysiology of systemic VT, astoxin binding to tubular subpopulations has an immedi-
ate effect to dilate the targeted tubule and (as a conse- compared to overlays with VTs on untreated sections.
In these sections, VT1 and VT2 were found in similarquence?) flatten the epithelial cells. No overt pathology
in these cells could be seen. tubule subpopulations. This means that not only can VT
bind to collecting ducts and distal and proximal tubules,Frozen serial section overlays showed precisely that
the same renal structures were reactive with both toxins. it can access these structures post glomerular filtration.
The fact that in situ immunostained toxins labeled tu-Thus, although differences in Gb3-mediated tissue tar-
geting are seen with respect to the lung, Gb3-mediated bules that were dilated and contained flattened epithelial
cells indicates that VT can have an immediate effect ontargeting in the kidney sections is not discriminatory.
However, not every proximal/distal tubule was bound renal fluid balance. The cell flattening may compromise
water reabsorption, resulting in local tubular dilation.by the toxins, which means that there is a difference in
Gb3 expression among tubules. VT binding in the over- The later renal pathology indicates that the tubular dila-
tion becomes more extensive, consistent with the glucos-lays was, for the most part, coincident with GLUT2,
indicating binding to the S1 and S2 segment of the convo- uria, a new predictor of outcome in this animal model.
We found lipid inclusions in the liver of VT2- (3 of 3),luted proximal tubule. It is in these segments of the
nephron where re-uptake of filtered glucose mainly takes but less in VT1- (1of 3) treated mice. This suggests that
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Fig. 8. VT1 / VT2 thin-layer chromatography
(TLC) overlay of renal and lung glycolipids.
Glycolipids were isolated from mouse lung
and kidney and an aliquot representing 20 mg
of tissue was separated by TLC and visualized
by orcinol (A). VT binding to Gb3 was de-
tected by TLC overlay with either VT1 (B)
or VT2 (C) as described [74]. Lane 1, adaGb3;
lanes 2, 3, standard glycolipid mixture at 0.25,
0.5 g each; lane 4, mouse renal glycolipids;
lane 5, mouse lung glycolipids. Glycolipid
standards are, from the top of the plate, gluco-
sylceramide, galactosylceramide, lactosylcera-
mide, Gb3, Gb4, Forssman glycolipid.
hemorrhage may initiate the more generalized pathol-
ogy. Since VT binding is restricted to pulmonary capillar-
ies, high local VT1 levels must accumulate to account
for the biodistribution observed. Extensive localized
hemorrhage and edema were evident. Margination of
polymorphonuclear neutrophils was seen throughout the
lung, indicating an active inflammatory response. The
high level of VT1 absorbed by the lungs could explain
the difference in LD50 for the toxins. The lungs could
function as an absorbing buffer, which permits less toxin
to reach the kidneys where it could otherwise have
caused more life-threatening pathology. However, we
did not assess the kidneys of mice given sub-lethal doses
of VT1.
Fig. 9. AdamantylGb3 (adaGb3)inhibition of VT/Gb3 binding. VT1 or A similar effect may be relevant to HUS in humans.VT2 were mixed with the indicated concentration of adaGb3 and tested
for residual binding to immobilized Gb3 in a RELISA [61]. (), VT1; Although the renal Gb3 increases with age [39], suscepti-
(), VT2. bility to VT-induced HUS is greatest in the very young
when the receptor is expressed in the glomerulus [38].
Thus, the increased expression of tubular Gb3 as a func-
tion of age might, to some extent, prevent toxin reabsorp-VT2 induces a more severe, generalized metabolic stress
tion by providing a similar, less crucial VT “sink.”such that lipid stores are mobilized for breakdown.
VT receptor isoformsLung targeting
The Gb3 species from kidney and lung clearly showSome degree of pulmonary symptoms has been re-
differential migration on TLC, indicating differencesported in a minor fraction of HUS patients [95]. VT1,
within the lipid moiety, which may affect VT bindingbut not VT2, was detected in lung sections obtained from
[99]. Mouse renal Gb3 has been reported to contain hy-a patient who died of HUS [22], despite the fact that
droxylated fatty acids [76], which would be consistentboth VT1 and VT2 were detected in the kidney of the
with its reduced TLC mobility. Overall, VT2 binds Gb3same patient [96]. Reported pulmonary histopathology
less effectively than VT1 [84] and this was reflected inincludes microthrombosis, capillary congestion in the al-
the TLC overlay both for renal and lung Gb3. This proce-veolar septa [97], and hemorrhage [98]. Mechanisms re-
dure, however, is semiquantitative and not optimum forsponsible for this pathology are thought to be the same
distinguishing the relative binding of Gb3 isoforms [82].as mechanisms causing angiopathy at the renal level.
Kinetic binding analysis and Gb3 characterization hasOur biodistribution study shows that the lungs are a
yet be performed to determine whether differential bind-major target for both toxins, although 10-fold more VT1
ing to Gb3 lipid isoforms could provide the basis of thethan VT2 was bound.
differential tissue recognition by VT1 and VT2.When detecting injected VT1 in the lung sections, we
found the toxin to be localized primarily in capillaries
Receptor analogue treatmentin some of the alveolar septa. Based on the extent of
It is clear that our first attempts to prevent VT/Gb3VT1-induced pathology, we expected the lung distribu-
tion to be more widespread. However, VT1-induced binding in vivo have failed. Despite the fact that adaGb3
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